跳至主要内容
临床试验/NCT00004293
NCT00004293Unknown2 期

Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease

National Center for Research Resources (NCRR)2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 1999年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
发起方
入组人数
24
试验地点
2

研究概览

简要总结

OBJECTIVES:

I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.

详细描述

PROTOCOL OUTLINE:

Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • PROTOCOL ENTRY CRITERIA:
  • -Disease Characteristics-- Gaucher disease with glucocerebrosidase deficiency confirmed by enzymatic or molecular assay At least 3 organ systems affected, based on the following criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary compromise Symptoms compromise daily activities or risk longevity No neurologic disease

排除标准

  • 未提供

研究者

发起方
National Center for Research Resources (NCRR)
申办方类型
Nih

研究点 (2)

Loading locations...

相似试验